Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit
Protagonist Therapeutics (Nasdaq: PTGX) has announced that Dinesh V. Patel, CEO, will present at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:40 p.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protagonist Therapeutics (Nasdaq: PTGX) has announced that Dinesh V. Patel, CEO, will present at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:40 p.m. EST. A webcast will be available for 90 days on the company’s Investors website. Protagonist focuses on peptide-based therapeutics, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis. They also collaborate with Janssen Biotech on oral IL-23 receptor antagonists. This upcoming presentation marks a key moment for stakeholders and potential investors.
Details
News Market Reaction – PTGX
The recorded move for PTGX in the trading session of this news was -1.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, Calif., Dec. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the upcoming JMP Securities Hematology and Oncology Summit taking place virtually on December 6, 2021.
Presentation details:
Date: Monday, December 6, 2021
Time: 1:40 p.m. EST
A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a recently completed Phase 2a study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled polycythemia vera trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.
The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds in development include PN-235, a second-generation oral interleukin-23 receptor antagonist candidate. Under the collaboration with Janssen, PN-235 is expected to advance into Phase 2 studies in psoriasis and new Phase 2 clinical studies in inflammatory bowel diseases.
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-jmp-securities-hematology-and-oncology-summit-301436894.html
SOURCE Protagonist Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.